Scientific and practical peer-reviewed journal for cardiologists and general practice physicians. Issued since 2005
ISSN 1819-6446 (Print) ISSN 2225-3653 (Online)
A.Y. Rychkov*, N.Y. Khor'kova, A.A. Bliznyakov
Branch of the Research Institute of Cardiology of the Siberian branch of the Russian Academy of Medical Science “Tyumen Cardiology Center”.
Melnikaite ul. 111, Tyumen, 625026 Russia
Appropriate use of warfarin is not in routine clinical practice despite convincing data of clinical studies on the possibility of effective reduction in frequency of thromboembolic complications associated with nonvalvular atrial fibrillation, particularly ischemic stroke. Confirmation of the efficacy and implementation of measures related to the effect on blood clotting and providing basically new possibilities to reduce the risk of ischemic events expected in the near future.
Key words: atrial fibrillation, stroke prevention, warfarin, antithrombotic therapy.
Rational Pharmacother. Card. 2010;6(4):522-527
* Corresponding author: rychkov@cardio.tmn.ru